The options for treating skin disease after haemopoietic progenitor cell transplant (HPCT) have broadened considerably over the last decade to include much more than topical steroids and emollients. This article reviews current and emerging therapies for chronic cutaneous GVHD, a well-recognised complication of HPCT. Alongside skin-directed therapies, there is now a wide range of systemic agents with differing targets for which an evidence base is emerging. Of particular interest, we summarise the role of electrocorporeal photopheresis, a therapy increasingly used in the United Kingdom to treat severe sclerodermoid manifestations of GVHD. We include a discussion of the expanding knowledge of the pathogenesis of cutaneous GVHD, which is informing our understanding and development of second line therapies (for example, the role of B cells and the utility of rituximab). Additionally, we draw attention to challenges encountered in the evaluation of chronic GVHD treatments and highlight recommendations for further research that may enable haematologists and dermatologists to provide better care for these patients. Finally, we present a clinical algorithm to aid the approach to treating limited and extensive disease and steroid refractory or persistent disease where steroid sparing may be necessary.
INTRODUCTION
There can be no more vivid and distressing reminder of the hazards of allogeneic haemopoietic progenitor cell transplantation (HPCT) than caring for a patient with disfiguring chronic cutaneous GVHD (ccGVHD). 1 Although severe physical and cosmetic symptoms and signs are now observed less frequently than 20 years ago, such patients will still regularly attend the allogeneic transplant follow-up clinic. Many other patients will suffer significant problems with mild or moderate ccGVHD. An understanding of the pathogenesis and therapeutic options for this condition is therefore essential for the transplant physician.
For many years, the pathogenic mechanisms that underlie GVHD had been poorly understood. Now, as we gradually gain a greater understanding of the immunological basis of ccGVHD, the complexity and diversity of this condition is beginning to emerge. It is to be hoped that with a better understanding of its pathogenesis, there is now reason to expect that the therapy of ccGVHD is about to enter an era of rapid development and improvement.
GVHD is a consequence of immunological interactions between donor T-cells and host tissues, predominantly involving the skin, gastrointestinal tract, liver, lungs and lymphoid tissues. 2 Classically, the features of acute GVHD were defined as those that occurred within 100 days of HPCT and those of chronic beyond 100 days. These definitions have been replaced by those in which the distinct clinical features of acute and chronic GVHD (cGVHD) are emphasised rather than the time frames in which they tend to occur. 3 cGVHD is common following allogeneic HPCT and the skin is involved in 490% of cases. 2 The cutaneous manifestations of cGVHD are numerous but broadly there are two main categories: lichenoid (includes violaceous scaly papules and plaques, nail dystrophy, mucosal ulceration) and sclerodermoid (includes morphoea-like, lichen sclerosus-like with follicular plugging and panniculitis). 4 Poikiloderma describes the atrophy, dyspigmentation and telangiectasia that may be seen in lichenoid disease. Lichenoid manifestations often appear earlier than sclerodermoid, and evidence is emerging that they have different responses to treatment. 2 Lichenoid disease sometimes evolves into sclerodermoid disease, and patients may suffer both forms simultaneously. 2 The cGVHD subclasses are summarised in Figure 1 .
THE CHALLENGE OF EVALUATING THERAPIES FOR ccGVHD
cGVHD patients represent a heterogeneous group, comprising those with single organ (typically skin, liver, gut or lung) or multiple organ involvement or a mixture of manifestations (acute and chronic), making meta-analysis difficult. Other factors contributing to heterogeneity include patient age (identified as a predictor of response to GVHD therapy), pretreatment regimens and type of HPCT. Between studies, the definitions of corticosteroid refractory differ and patients have often been heavily pretreated with widely varying therapies. Few studies concentrate solely on cutaneous manifestations and are often not large enough to determine whether the type of skin manifestation (for example, lichenoid vs sclerodermoid) is important for response to treatments. Indeed, studies are often not sufficiently powered to measure responses.
The assessment of therapeutic response differs widely between studies (most are very subjective and non-blinded; a few are blinded and use objective measures). Primary end points have included survival, CR, PR (50% subjectively assessed reduction in disease) and corticosteroid tapering. 5 No fixed protocols for this have been used, and clinicians have often been non-blinded. 5 Together, these challenges have impacted upon the availability of sufficiently strong evidence for GVHD therapies.
The National Institutes of Health (NIH) drew up consensus criteria in 2006 to address concerns over the lack of concrete methodology for diagnosing and assessing GVHD. 5 Acute and cGVHD were distinguished by clinical signs and subcategories of disease were described. Accordingly, acute GVHD can be subcategorised into classic and late disease, and cGVHD into classic and overlap disease. It remains to be seen whether the use of the NIH criteria contributes to the standardisation of future clinical trials. 6 describes a three-stage process underlying GVHD. First, a conditioning regimen causes tissue damage in the host. Second, donor T-cells become activated against the host and clonal expansion ensues. Finally, release of inflammatory cells and cytokines (for example, TNF-a, IL-1) occurs, which causes further tissue damage in the host. This provides a useful framework when discussing therapeutic options, although this model omits the roles of other cells such as B-cells, natural killer cells and dendritic cells. Theories underlying the pathogenesis of cGVHD include: thymic dysfunction caused by acute GVHD; 7 the role of TGF-b in promoting cGVHD 8 and involvement of auto-Abs and of regulatory T-cells (T reg ; see below). These theories are now beginning to be confirmed in humans. 8 Several mechanisms are likely to work in concert, and these will vary in different patients. In the future we may be able to provide tailored therapies for individual patients. 8 B-cells in GVHD Newer roles for B-cells including immunostimulation through Ag presentation and immunoregulation are being recognised. 9 It is unclear whether the auto-Abs detected in patients with ccGVHD are directly pathogenic or just a marker of B-cell involvement. Auto-Abs to PDGF receptor, which activate fibroblasts, have been detected in patients with scleroderma and ccGVHD, and auto-Abs to extracellular matrix protein 1 in patients with lichen sclerosus. 10, 11 Patients receiving sex-mismatched HSCT have higher levels of B-cell-activating factor, another biomarker of unknown significance. In addition, allo-Abs to Y chromosome mHA have been identified, and treatment with rituximab shown to deplete them and offer protection against GVHD. 12 Regulatory T-cells Current knowledge of T regs has led to their classification into two subsets. 13 Natural T reg develop in the thymus and are CD4 þ CD25 þ FOXP3 þ . The FOXP3 gene encodes the forkhead-winged-helix transcription factor, scurfin and appears to act as a master regulator of T reg function. Inducible T regs develop through the activation of mature T-cells and become either type I (secreting IL-10) or T H 3 type (secreting TGF-b). T regs suppress autoreactive T-cells to promote immune tolerance. T reg cells may be deficient in the tissues and/or peripheral blood of patients with cGVHD. Reduced number and decreased function of CD4 þ CD25 þ T reg have been observed in the peripheral blood of patients with type I diabetes, rheumatoid arthritis and systemic lupus erythematosus. 13, 14 Recently, Antiga et al.
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investigated lesional biopsies and peripheral blood of patients with systemic sclerosis, with morphoea and inflammatory and healthy controls. A depletion of natural T reg was demonstrated in the scleroderma patients both in skin lesions and peripheral blood, suggesting a true downregulation of these cells. 15 Di Biaso et al.
16 studied 18 patients with cGVHD (not exclusively limited to the skin) and showed that responders to extracorporeal photochemotherapy (ECP) had increased numbers of T reg cells in the peripheral blood and a correspondingly diminished secretion of IL-17. IL-17 is secreted by T H 17 cells, which may be antagonistic to T regs . 16 A retrospective analysis of 95 patients with gastrointestinal GVHD concluded that patients with GVHD had decreased numbers of T reg in their mucosa. 17 
THERAPIES FOR ccGVHD
Corticosteroids-both topical and systemic-are the mainstay of the treatment of ccGVHD. Currently there is little consensus over the universal definition of cortiocosteroid refractory cGVHD and as to the optimal strategy for corticosteroid-refractory disease. In addition to the topical therapies and systemic drugs used in this condition, ECP has emerged as an important treatment modality for selected patients.
Limited disease: skin-directed therapy Skin-directed therapy may be used for limited ccGVHD or as adjuvant therapy in extensive disease. They are summarised in Table 1 . For localised mucocutaneous cGVHD, topical therapies include corticosteroids for the skin, oestrogen creams for vaginal mucosa and corticosteroid mouth washes for oral mucosa 1, [18] [19] [20] There is good evidence to show that the effects of budesonide mouthwashes are cumulative. 21 In a retrospective study, Sari et al. 21 reported good response rates (83%) in patients using budesonide (a potent corticosteroid) mouthwash compared with controls. More recently, an open, randomised, multicentre study has added weight to these results (Table 1) , and a larger phase III study is underway.
An array of corticosteroid creams and ointments of different potencies are available, which have a particular importance in patients with mild localised disease and a high risk of malignant 
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Managing chronic cutaneous GVHD CJ Rodgers et al Managing chronic cutaneous GVHD CJ Rodgers et al relapse. 22 The evidence available comprises reports from retrospective studies and small uncontrolled trials. 23 Tacrolimus (FK506) and pimecrolimus are calcineurin inhibitors used topically for ccGVHD. Pimecrolimus, inhibits mast cell histamine release. 24, 25 Both drugs suppress the production of cytokines (for example, IL-2, TNF-a) by antagonising helper T-cell activation. The most common side effect is a transient cutaneous burning sensation. 26 Effects from systemic absorption are minimal and there appears to be no increased risk of systemic infection or nephrotoxicity. 25, 26 Some patients are photosensitive (drug-induced) and many are taking oral immunosuppressive drugs such as CYA. In our experience, ccGVHD often follows initial sunburn and so advice on photoprotection is an important part of the treatment regimen to reduce the future risk of skin cancer. Patients should cover up, wear hats with broad brims and apply broad spectrum sunblock creams (at least SPF 15) to exposed sites.
The evidence for topical calcineurin inhibitors is currently limited to a collection of case reports and case series. 24, [26] [27] [28] The largest of these series was carried out by Choi et al. 25 (18 patients; 11 with generalised, 7 with localised corticosteroid-refractory ccGVHD) using 0.1% tacrolimus ointment. Patients were assessed using patient reports, dermatological examination, side-by-side comparison with control cream and by post-treatment follow-up. In all, 72% patients responded (defined as relief of erythema and pruritus). Two patients reported loss of efficacy with time but it is unclear whether the disease had progressed or there was lack of compliance or tachyphylaxis. 25 Pimecrolimus has been recommended for milder ccGVHD, facial involvement and for use in children as it is tolerated better on the skin. 23 Cold black tea compresses have been recently advocated for supportive therapy to reduce inflammation in ccGVHD but there is currently no good quality evidence base for this treatment. 23 Phototherapy and photochemotherapy (UVA with psoralen; PUVA) UV radiation is used in a variety of dermatological conditions including ccGVHD. The types of radiation employed in the management of ccGVHD and their penetration are summarised in Table 2 .
Numerous mechanisms for the action of UV radiation in the skin have been proposed, including the induction of apoptosis, immunomodulation and antiproliferation of skin cells. 23 When commencing patients on phototherapy, they are advised of the risks (carcinogenesis, erythema, side effects of psoralen) and a minimal erythema dose is obtained (the minimum dose of UV irradiation to cause erythema of the skin) in order that the starting dose of UV can be calculated.
Optimal dosing strategies for use of phototherapy and photochemotherapy are currently not standardised. In terms of the rationale for which therapy to choose, the extent of penetration of UV radiation is likely to be important. Lichenoid lesions are more superficial and may respond to UVB whereas sclerodermoid lesions are more likely to respond to the deeper penetrating UVA. 23 Phototherapy and photochemotherapy used alongside immunosuppressive therapy have been reported to be successful in both lichenoid and sclerodermoid ccGVHD. 29 There are only a few case reports and small studies demonstrating photochemotherapy with 8-methoxypsoralen plus UVA light (PUVA) to be successful for treating sclerodermoid ccGVHD. 30, 31 Long-wavelength UVA (300-400 nm) alone was used to treat 10 patients with ccGVHD, and is reported to have previously been successfully used in scleroderma. 29 Reversible tanning and mild erythema were the only reported side effects whereas PUVA can induce nausea and vomiting and skin photosensitivity. 29 The evidence for UVA therapy in sclerodermoid ccGVHD, recently systematically reviewed, is limited (15 patients reported). 32 UVA-1 comprises a narrow range of UV radiation in the range 340-400 nm and has been found to be useful in sclerodermoid ccGVHD, although the number of patients reported in the literature is o15. 33 Proposed mechanisms for its effectiveness include the induction of apoptosis in T-cells (UVA-1 can penetrate deeply to affect T-cells directly), suppression of proinflammatory cytokines and induction of cytokine production in fibroblasts. 33 UVA-1 is well tolerated although the risk of photocarcinogenesis has not been fully defined.
A small study on the use of narrowband UVB (311 nm) carried out by Enk et al. 34 reported complete resolution of lichenoid lesions in one patient and diminished pruritus in two patients with sclerodermoid ccGVHD treated with narrowband UVB. The sclerodermoid lesions did not change. In all, 10 pediatric patients treated with narrowband UVB alongside systemic immunosuppression showed promising results, with 80% of patients achieving CR of their GVHD after a median of 7.5 weeks of treatment. 35 UVB is less carcinogenic than PUVA, and narrowband UVB less erythrogenic.
Extensive disease
Initial systemic agents. For more extensive skin disease, standard treatment comprises oral corticosteroids (usually starting with prednisolone 1 mg/kg per day) with oral tacrolimus or CYA. 22 The CYA-corticosteroid combination was first shown to be effective in a study over 20 years ago. 36 A more recent study suggests that the combination allows for steroid-sparing rather than producing an increased efficacy. 37 Alternative agents are required for corticosteroid-refractory ccGVHD (up to 40% of patients) or patients with intolerable corticosteroid side effects. 12 As corticosteroids are a mainstay of treatment of cGVHD, they generally comprise the control arm in trials of therapy for systemic cGVHD. The Cochrane collaboration recently systematically reviewed the use of oral corticosteroid regimens for the treatment of acute and cGVHD. Unfortunately, only two, poor quality acute GVHD trials met the revised inclusion criteria and a meta-analysis could not be carried out owing to differences in the clinical question being addressed. 38 Hence, the impact of corticosteroids upon survival in cGVHD remains unknown and their effect on quality of life could not be evaluated because of lack of evidence. Obtaining this information is of importance because of the side effect profile of corticosteroids and to find answers to questions regarding optimal duration of treatment and tapering regimens.
Mycophenolate mofetil inhibits lymphocytic purine synthesis and has often been used as second-line therapy despite the potential limitations of gastrointestinal discomfort and diarrhoea, leukopenia and thrombocytopenia. 39 Early reports suggested that it was a useful therapy in cGHVD, which led to the development a well-designed double-blinded randomised trial. 40 The trial was closed early as it was observed that mycophenolate mofetil had no effect and increased the risk of infections. Concerns over the potential for mycophenolate mofetil to increase the risk of relapse in patients with myeloid malignancy has also been reported. 39 MSC MSC are known to have immunosuppressive effects and have been shown to be of benefit, particularly in patients with acute Managing chronic cutaneous GVHD CJ Rodgers et al GVHD. 41 These effects have been harnessed in their recent application in treating patients with cGVHD. There are as yet no prospective trials but early reports suggest a beneficial effect in sclerodermoid ccGVHD. 42 These results are promising but concerns surrounding MSC use such as the attenuation of the graft-versus leukaemia effect and potential for MSCs to facilitate malignant relapse (by enhancing the proliferation of leukaemic cells) warrant further study. 42 
ECP
Originally developed for treating cutaneous T-cell lymphoma, ECP has been employed in the management of corticosteroidrefractory ccGVHD in the United Kingdom since 1994. 43 ECP involves leukopheresis followed by photoactivation (using either oral methoxypsoralen or direct injection of psoralen (Uvadex, Therakos Inc., Wokingham, UK) into the buffy coat and UVA) and finally reinfusion. 43 The treatment has a very good side-effect profile, with usually o1% reported adverse effects. 44 Nausea is common and other mild transient effects include headache, fever and chills. 44 More serious adverse effects are rare (o1%) and include hypotension, vasovagal syncope, anaemia and abnormal clotting secondary to heparin flushes. 44 Good venous access is required for the procedure and can be either peripheral (16-18G) or central. The latter can lead to localised or systemic infections or the development of thrombi. There is immunosuppression, no increased risk of non-line-related infection or of secondary malignancy with ECP.
In cGVHD, the mechanism of action of ECP is unclear but there is evidence for efficacy. In lymphoma treatment, apoptosis is induced in leukocytes by psoralen covalently binding to DNA. When these apoptotic cells are reinfused, a set of tumour suppressor cells are induced to proliferate, which kill malignant leukocytes. 43, 44 In 2005, a UK photopheresis expert group was formed to review the evidence for using ECP in cGVHD. Cutaneous and mucosal forms were consistently associated with high response rates and of the 18 studies on cutaneous disease, the mean response rate was 68%. 43 Response rates were measured using varying skin scoring systems. However, as many of the reports and studies were produced before the NIH assessment criteria (2006), much of the data contain non-standardised and subjective assessments of patient responses. 43 Moreover, study heterogeneity and the heavily pretreated nature of the patients complicated the analysis of these data. Since then, prospective randomised control trials have been reported such as the study by Flowers et al. 45 (95 patients) comparing ECP þ standard therapy to standard therapy alone. The primary end point was a change in total skin score (TSS) measured by a blinded physician. The method for calculating TSS is shown in Table 3 . Statistically significant results were not obtained for the primary end point but, at 12 weeks, the proportion of patients achieving X50% reduction in corticosteroid use and 425% improvement in TSS was greater in the ECP arm and this was statistically significant, demonstrating the potential for ECP to facilitate corticosteroid sparing. A summary of studies is shown in Table 4 .
The prospective design, relatively large number of patients, blinded assessments and well-balanced patient demographics in both arms are strengths of this study. The results were, however, only analysed at the 12-week time point as a large number of patients crossed over into the ECP group. 45 Thus, the nonsignificant primary end point results may have been affected by the short duration of treatment. The UK consensus committee suggest at least 6-12-month therapy. Moreover, bias may have been introduced as adjustments to corticosteroid doses were made by a non-blinded investigator. 45 The response to ECP in cGVHD is difficult to predict but some data suggest that higher response rates are observed in patients with sclerodermoid disease. In a retrospective study, which included 56 patients with skin GVHD, Couriel et al. 46 reported that 67% of patients with sclerodermoid disease responded to ECP. Most recently, a large study of ECP in ccGVHD (82 patients) has been published demonstrating the efficacy of receiving bimonthly ECP for 6 months. 47 Furthermore, a randomised, openlabel crossover ECP study in 29 patients receiving a 24-week course of ECP demonstrated a 31% complete or partial skin response with reductions in TSS. 48 With regard to quality of life, a benefit was demonstrated in Flowers' study, 45 but as this was an open-label trial, improvements observed in the ECP arm could be because of the placebo effect. 45 Clearly there are ethical problems implicit with a sham ECP procedure.
Future work might include validation of the TSS and more rigorously investigating how lichenoid or sclerodermoid manifestations may respond differently to ECP. No optimum treatment Managing chronic cutaneous GVHD CJ Rodgers et al schedule has been determined. Thus, considerable variety is seen in ECP studies published, which makes them more difficult to compare. 39 A better understanding of GVHD pathogenesis would aid our knowledge and refinement of ECP as a therapy. No discussion of ECP would be complete without pointing out that ECP is only available at specialist centres, is time-consuming for patients and medical staff, and is expensive.
Second-line drugs targeting specific pathways Second-line therapy is potentially required in 50% of cases. 39 The choice of second-line therapy is largely down to the individual clinician, their approach to treating individual patients and the availability of resources. The consensus report on second-line therapies notes that there is also no uniformly accepted definition of corticosteroid-refractory disease. 39 Significant variation exists in drug targets for second-line therapies currently in use (Figure 2) . Selected second-line systemic therapies are summarised in Table 4 . Pentostatin, an adenosine deaminase inhibitor inhibits the clonal expansion of donor CD4 þ and CD8 þ T-cells. 6 It is an i.v. drug with a simple dosing regimen (given every 2 weeks) which is an advantage when treating patients with chronic disease. 49 A recent study in a heavily pretreated patient population with cutaneous and/or liver GVHD showed that in those with cutaneous disease, 69% of those with lichenoid features improved and 52% of those with sclerodermoid features improved. 50 The largest cGVHD study in a pediatric population (51 patients, 78% lichenoid disease, 53% sclerodermoid) demonstrated a 50% response rate in lichenoid disease and a 59% response rate in sclerotic disease. 49 Alefacept is a fusion protein, comprising a CD2-binding portion attached to the Fc segment of human IgG1 that specifically inhibits the activation of memory T-cells by the blocking of and LFA-3/CD2 interaction between APC and the memory T-cell. It can also induce apopotosis in memory T-cells. It has a selective effect on effector (rather than central) memory T-cells and is approved in the United States for use in psoriasis. 51, 52 The evidence supporting its use is limited to a few very small studies, which have shown promising results and good tolerability. 51, 52 The overall response rates (which includes cutaneous, mucocutaneous, liver, lungs, gut and peripheral nervous system GVHD) were high (83%) but clinical judgement rather than validated scoring tools were used. Neither alefacept nor pentostatin are currently widely used, and larger studies are required to confirm these preliminary results.
Other T-cell-directed agents are currently under investigation in murine models of ccGVHD. The agonist MoAb anti-CD137 has been shown to reverse skin fibrosis, ulceration and alopecia in mice modified to manifest signs of cGVHD in the skin, liver and lungs.
53 CD137, part of the TNF receptor superfamily, co-stimulates CD8 þ T-cells and the authors hypothesised that therapeutic response to anti-CD137 was because of the specific depletion of CD4 þ T-cells and non-specific depletion of B-cells. 53 Interestingly, if given as GVHD prophylaxis, lethal acute GVHD is induced by this Ab, the reasons for which are not known. 54 Safety has been shown in phase I trials; phase II chemotherapy trials are underway, although there are no trials yet in cGVHD. 
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Agents targeting inflammatory cytokines Agents targeting inflammatory cytokines have been used with success to treat psoriasis and rheumatoid arthritis. Etanercept and daclizumab both inhibit cytokines. Daclizumab (a humanised IgG1) which inhibits the IL-2 receptor a, a receptor important in T-cell proliferation, has been investigated mainly in small numbers of children, the majority of which had acute rather than cGVHD. 1 The most recent study published, which included patients with ccGVHD, was in 2006 that reported four patients with a 25% CR rate. 55 Ferrara 6 carried out a small open-label study of etanercept, a TNF-a receptor type II fusion protein, which blocks the action of TNF-a by competing for the TNF-a receptor. TNF-a assays revealed levels correlated with disease severity and also pointed to them being a possible prognostic factor. In skin, 84% CR rates were observed. These are positive early results and studies are ongoing.
Targeting B-cells B-cell depletion was considered a potential therapy after the serendipitous discovery that an immune thrombocytopenic patient's ccGVHD improved when treated with rituximab (a chimeric human-murine monoclonal IgG Ab targeted at the B-cell CD20 receptor). 9 Rituximab depletes B-cells by numerous mechanisms leading to a concomitant decrease in T-cell activation and increase in T reg . 9 Depletion of Abs by rituximab may also occur as CD20-positive plasma cells have also been described. 10 The efficacy of rituximab has recently been systematically reviewed and a meta-analysis carried out. 12, 56 Seven studies were included (three prospective trials) and the range of response rates for ccGVHD was 13-100%. The wide variation is probably because of varying assessments of response and small patient populations. 56 However, the fact that studies were deemed homogeneous enough to be pooled for metaanalysis is positive as few meta-analyses of cGVHD trials exist. Research is ongoing; however, Kim et al. 57 recently published a study involving 22 patients with ccGVHD and demonstrated a cutaneous response rate of 77%.
Targeting fibrosis: imatinib Imatinib is a tyrosine kinase inhibitor used to treat CML and is emerging as a useful agent for the effective second-line management of fibrotic ccGVHD. It inhibits PDGF receptor and TGF-b, which in experimental models, causes a decrease in fibrosis. 58 Therefore, it was postulated that it may be useful in the treatment of patients with sclerotic/fibrotic manifestations of ccGVHD, many of whom have been shown to be positive for PDGF receptor Abs. 58 It was also serendipitously found useful as a cGVHD therapy when imatinib used to treat patients with CML was found to also effectively treat the cGVHD. 59 As earlier case reports, both prospective and retrospective studies have been undertaken. 58, 60, 61 In a recent prospective study, 19 patients (17 with cutaneous sclerotic GVHD) were treated with imatinib and followed up over 17 months. Prospectively designed objective response criteria as had been previously used in other studies were employed in this study. A response rate solely for cutaneous disease was not reported but the overall response rate at 18 months was promising (84%). 58 The results of a larger prospective study (38 patients with ccGVHD treated with imatinib) have recently been analysed and add weight to previous studies. 62 A phase II open-label trial more specific to cutaneous GVHD is underway (National Cancer Centre) and the results are awaited with interest. Two other small molecule, abl kinase and PDGF receptor inhibitors (dasatinib and nilotinib), more potent than imatinib are also in the early stages of investigation. 63 
OTHER EMERGING THERAPIES
Biologics are being continuously developed and the most recent to be investigated in ccGVHD is tocilizumab, an anti-IL-6 receptor Ab. 64 Additionally, drugs that can be administered to patients after transplant to suppress the effects of GVHD in the skin are interesting. Pravastatin, an 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, was investigated some years ago and is receiving more attention recently in experimental models in the context of cGVHD. In the context of established disease, pravastatin was disappointing. Hori et al. 65 undertook a prospective study using 10 mg per day of pravastatin in 18 patients (16 with ccGVHD), but only 2 patients with cutaneous disease responded. However, murine models show that there is a significantly slower onset of cutaneous GVHD and attenuated collagen deposition in mice treated with pravastatin from Figure 3 . A clinical algorithm for the approach to treating cutaneous GVHD.
transplantation to 1 month after transplant (a prophylactic effect). 66 Further research is ongoing.
TREATING ccGVHD: A CLINICAL ALGORITHM
Despite the varied number of treatments available and the patchiness of the clinical evidence, which underpins their use, we have found it helpful to develop a treatment algorithm for ccGVHD ( Figure 3 ). Our practice is initially to apply betamethasone or clobetasol propionate to lichenoid GVHD affecting the body, and to use the weak hydrocortisone on the face. When such therapy fails, more potent formulations such as clobetasone butyrate may be used. Although there are potential risks of skin atrophy with long-term use of topical corticosteroids, in our experience, patients need to be reassured that this is very unlikely to occur with short or medium term use, in order to aid compliance. Ointments are generally preferable to creams, although some patients dislike their greasy nature. Itch secondary to dry skin may be reduced with emollients and soap substitutes. Systemic therapies including ECP may also be necessary as outlined in the figure.
CONCLUSION
New therapies for ccGVHD are emerging, particularly for corticosteroid-refractory disease. Amongst them, the evidence for ECP, rituximab and imatinib is particularly convincing. The investigation of these new therapies in a rigorous manner with large, well-designed blinded randomised control trials is now required. Optimal doses and treatment regimes should be determined for each therapy and assessment of the skin should be included in any clinical trial in ccGVHD. We should work to overcome the challenges of clinical trials in potentially heterogeneous populations with ccGVHD by using standardised tools to evaluate the clinical signs, measure outcome and record the impact upon quality of life. The need for evaluation of promising second-line therapies provides an exciting opportunity for both haematologists and dermatologists.
